ID Biomedical Corp.
http://www.idbiomedical.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ID Biomedical Corp.
Keeping Track: Seqirus Pandemic Flu Vaccine Approved; Trevena Resubmits Oliceridine
The latest drug development news and highlights from our US FDA Performance Tracker.
Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved
Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.
GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
Flu Vaccine Production Down Slightly This Season; Strains Get Overhaul
FDA encourages people to get vaccinations since two of the three virus strains in this season’s flu vaccines differ from last season’s; several manufacturers plan to distribute slightly fewer doses in 2012-2013 than in the prior year.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Drug Delivery
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice